Johnson & Johnson lifted its 2014 earnings forecast for a third time on Tuesday, fueled in part by revenue gains from its new blockbuster hepatitis C treatment Olysio.

But shares of the world’s biggest health care products maker slipped as investors worried about looming competition for the drug, which has already generated nearly $2 billion in global sales so far this year.